Abstract | BACKGROUND: MATERIALS AND METHODS: We reviewed the records of 1030 patients with estrogen receptor-positive, HER2-normal stage I breast cancer and RS available. RSs were correlated with clinicopathologic characteristics, treatment, and outcome. RESULTS: Patients with pathologic (p)T1a, pT1b, and pT1c disease did not differ in distribution of low, intermediate, and high RS (P = .673). Overall, fewer than 10% of patients had a high RS. Histologic grade 1, nuclear grade 1, and low Ki-67 expression had only 1%, 0%, and 6% of high RSs, respectively. Among patients with intermediate RSs, 41% with pT1b and 46% with pT1c disease received CT. Among patients with intermediate RSs, for pT1b disease, distant disease-free survival (DDFS) did not differ between hormonal therapy (HT) alone and CT with HT (P = .752); for pT1c, DDFS was superior for CT with HT (P = .020). Histologic grade was the only independent prognostic factor of DDFS (P = .0007, 1 vs. 3; P = .035, 2 vs. 3); RS did not predict DDFS (P = .083, high vs. low; P = .066, intermediate vs. low). CONCLUSION: The added value of RS to known prognostic factors appears limited to patients with pT1b breast cancer. However, this study lacked long-term follow-up.
|
Authors | Fanny Le Du, Ana M Gonzalez-Angulo, Minjeong Park, Diane D Liu, Gabriel N Hortobagyi, Naoto T Ueno |
Journal | Clinical breast cancer
(Clin Breast Cancer)
Vol. 15
Issue 6
Pg. 458-66
(Dec 2015)
ISSN: 1938-0666 [Electronic] United States |
PMID | 26233757
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Topics |
- Adult
- Aged
- Aged, 80 and over
- Breast Neoplasms
(classification, drug therapy, genetics)
- Chemotherapy, Adjuvant
- Female
- Gene Expression Profiling
(methods)
- Gene Expression Regulation, Neoplastic
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Neoplasm Recurrence, Local
(genetics)
- Neoplasm Staging
- Prognosis
- Proportional Hazards Models
- Retrospective Studies
- Reverse Transcriptase Polymerase Chain Reaction
- Risk
- Treatment Outcome
|